Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies-Reference-Cited by-同舟云学术

Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies

Published:2023-08-14 Issue:4 Volume:19 Page:788-799
ISSN:1673-5374
Container-title:Neural Regeneration Research
language:en
Short-container-title:

Author:

Duncan R. Scott¹,Riordan Sean M.¹,Gernon Matthew C.¹,Koulen Peter¹²^ORCID

Affiliation:

1. Department of Ophthalmology, School of Medicine, University of Missouri, Kansas, MO, USA

2. Department of Biomedical Sciences, School of Medicine, University of Missouri, Kansas, MO, USA

Abstract

Cannabinoids are lipophilic substances derived from Cannabis sativa that can exert a variety of effects in the human body. They have been studied in cellular and animal models as well as in human clinical trials for their therapeutic benefits in several human diseases. Some of these include central nervous system (CNS) diseases and dysfunctions such as forms of epilepsy, multiple sclerosis, Parkinson’s disease, pain and neuropsychiatric disorders. In addition, the endogenously produced cannabinoid lipids, endocannabinoids, are critical for normal CNS function, and if controlled or modified, may represent an additional therapeutic avenue for CNS diseases. This review discusses in vitro cellular, ex vivo tissue and in vivo animal model studies on cannabinoids and their utility as therapeutics in multiple CNS pathologies. In addition, the review provides an overview on the use of cannabinoids in human clinical trials for a variety of CNS diseases. Cannabinoids and endocannabinoids hold promise for use as disease modifiers and therapeutic agents for the prevention or treatment of neurodegenerative diseases and neurological disorders.

Publisher

Medknow

Subject

Developmental Neuroscience

Reference122 articles.

1. Effect of inhaled cannabis for pain in adults with sickle cell disease: a randomized clinical trial;Abrams;JAMA Netw Open,(2020)

2. Δ9 -Tetrahydrocannabinol promotes functional remyelination in the mouse brain;Aguado;Br J Pharmacol,(2021)

3. Buccally absorbed cannabidiol shows significantly superior pain control and improved satisfaction immediately after arthroscopic rotator cuff repair: a placebo-controlled, double-blinded, randomized trial;Alaia;Am J Sports Med,(2022)

4. The pharmacokinetics, efficacy and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial;Almog;Eur J Pain,(2020)

5. A placebo-controlled investigation of the analgesic effects, abuse, liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans;Arout;Br J Clin Pharmacol,(2022)